These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sclerotiorin inhibits protein kinase G from Mycobacterium tuberculosis and impairs mycobacterial growth in macrophages. Chen D; Ma S; He L; Yuan P; She Z; Lu Y Tuberculosis (Edinb); 2017 Mar; 103():37-43. PubMed ID: 28237032 [TBL] [Abstract][Full Text] [Related]
4. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
6. The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway. Negi A; Sharma R Eur J Med Chem; 2024 Feb; 265():116058. PubMed ID: 38128237 [TBL] [Abstract][Full Text] [Related]
7. Proteome remodeling in the Mycobacterium tuberculosis PknG knockout: Molecular evidence for the role of this kinase in cell envelope biogenesis and hypoxia response. Lima A; Leyva A; Rivera B; Portela MM; Gil M; Cascioferro A; Lisa MN; Wehenkel A; Bellinzoni M; Carvalho PC; Batthyány C; Alvarez MN; Brosch R; Alzari PM; Durán R J Proteomics; 2021 Jul; 244():104276. PubMed ID: 34044169 [TBL] [Abstract][Full Text] [Related]
8. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality? Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243 [TBL] [Abstract][Full Text] [Related]
9. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum. Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524 [TBL] [Abstract][Full Text] [Related]
10. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
11. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis. Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907 [TBL] [Abstract][Full Text] [Related]
12. Ge P; Lei Z; Yu Y; Lu Z; Qiang L; Chai Q; Zhang Y; Zhao D; Li B; Pang Y; Liu CH; Wang J Autophagy; 2022 Mar; 18(3):576-594. PubMed ID: 34092182 [TBL] [Abstract][Full Text] [Related]
13. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Lin PL; Dartois V; Johnston PJ; Janssen C; Via L; Goodwin MB; Klein E; Barry CE; Flynn JL Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14188-93. PubMed ID: 22826237 [TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
15. Key residues in Mycobacterium tuberculosis protein kinase G play a role in regulating kinase activity and survival in the host. Tiwari D; Singh RK; Goswami K; Verma SK; Prakash B; Nandicoori VK J Biol Chem; 2009 Oct; 284(40):27467-79. PubMed ID: 19638631 [TBL] [Abstract][Full Text] [Related]
16. Identifying RO9021 as a Potential Inhibitor of PknG from Arica-Sosa A; Alcántara R; Jiménez-Avalos G; Zimic M; Milón P; Quiliano M ACS Omega; 2022 Jun; 7(23):20204-20218. PubMed ID: 35721990 [TBL] [Abstract][Full Text] [Related]
17. Structural basis for the specific inhibition of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Scherr N; Honnappa S; Kunz G; Mueller P; Jayachandran R; Winkler F; Pieters J; Steinmetz MO Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12151-6. PubMed ID: 17616581 [TBL] [Abstract][Full Text] [Related]
18. PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis. Rieck B; Degiacomi G; Zimmermann M; Cascioferro A; Boldrin F; Lazar-Adler NR; Bottrill AR; le Chevalier F; Frigui W; Bellinzoni M; Lisa MN; Alzari PM; Nguyen L; Brosch R; Sauer U; Manganelli R; O'Hare HM PLoS Pathog; 2017 May; 13(5):e1006399. PubMed ID: 28545104 [TBL] [Abstract][Full Text] [Related]
19. Fighting tuberculosis by drugs targeting nonreplicating Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518 [TBL] [Abstract][Full Text] [Related]